A clinical trial of somatic and germline analyses for healthy longevity in a postoperative cancer patient

Naoki Hayashi, Yohsuke Kuroda, Tomoko Saito, Yusuke Tsuruda, Atsushi Niida, hajime otsu, Hidetoshi Eguchi, Takaaki Masuda, Yutaka Suzuki, Shoji Natsugoe, Koshi Mimori

Research output: Contribution to journalArticle

Abstract

Purpose: Recent developments in molecular-targeted therapies have improved the clinical outcome of cancer patients; however, the issue of adverse effects due to treatments has often gone unconsidered. We herein report the results of a clinical trial of dual genomic analyses for healthy longevity in a postoperative cancer patient. Methods: We performed dual genomic analyses for a representative 79-year-old rectal cancer patient who relapsed with liver metastasis. First, we determined single-nucleotide polymorphisms according to the constitution and disease risk in the genomic DNA from the patient’s saliva by referring to the data of 10,000 Japanese patients obtained from Yahoo Japan Corporation. Second, we conducted whole-exome sequencing to detect druggable mutations in the primary tumour. Results: Forty of 59 determinable characters related to the constitution were consistent with the clinical phenotype. Several diseases classified as ‘high risk’ diseases actually occurred during the patient’s clinical course. Of the 129 significant mutations, we identified somatic mutations in BRAF, PIK3CA, and SMAD4 as targets. Conclusion: The dual genomic examination will improve the follow-up observation system to support primary care doctors in the social community for taking care of postoperative cancer patients.

Original languageEnglish
Pages (from-to)738-747
Number of pages10
JournalSurgery today
Volume49
Issue number9
DOIs
Publication statusPublished - Sep 10 2019

Fingerprint

Clinical Trials
Neoplasms
Constitution and Bylaws
Mutation
Molecular Targeted Therapy
Exome
Postoperative Care
Rectal Neoplasms
Saliva
Single Nucleotide Polymorphism
Primary Health Care
Japan
Observation
Neoplasm Metastasis
Phenotype
Liver
DNA
Therapeutics

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

A clinical trial of somatic and germline analyses for healthy longevity in a postoperative cancer patient. / Hayashi, Naoki; Kuroda, Yohsuke; Saito, Tomoko; Tsuruda, Yusuke; Niida, Atsushi; otsu, hajime; Eguchi, Hidetoshi; Masuda, Takaaki; Suzuki, Yutaka; Natsugoe, Shoji; Mimori, Koshi.

In: Surgery today, Vol. 49, No. 9, 10.09.2019, p. 738-747.

Research output: Contribution to journalArticle

Hayashi, N, Kuroda, Y, Saito, T, Tsuruda, Y, Niida, A, otsu, H, Eguchi, H, Masuda, T, Suzuki, Y, Natsugoe, S & Mimori, K 2019, 'A clinical trial of somatic and germline analyses for healthy longevity in a postoperative cancer patient', Surgery today, vol. 49, no. 9, pp. 738-747. https://doi.org/10.1007/s00595-019-01789-7
Hayashi, Naoki ; Kuroda, Yohsuke ; Saito, Tomoko ; Tsuruda, Yusuke ; Niida, Atsushi ; otsu, hajime ; Eguchi, Hidetoshi ; Masuda, Takaaki ; Suzuki, Yutaka ; Natsugoe, Shoji ; Mimori, Koshi. / A clinical trial of somatic and germline analyses for healthy longevity in a postoperative cancer patient. In: Surgery today. 2019 ; Vol. 49, No. 9. pp. 738-747.
@article{50538e1d5e05483798d5ae3ae42ab7e4,
title = "A clinical trial of somatic and germline analyses for healthy longevity in a postoperative cancer patient",
abstract = "Purpose: Recent developments in molecular-targeted therapies have improved the clinical outcome of cancer patients; however, the issue of adverse effects due to treatments has often gone unconsidered. We herein report the results of a clinical trial of dual genomic analyses for healthy longevity in a postoperative cancer patient. Methods: We performed dual genomic analyses for a representative 79-year-old rectal cancer patient who relapsed with liver metastasis. First, we determined single-nucleotide polymorphisms according to the constitution and disease risk in the genomic DNA from the patient’s saliva by referring to the data of 10,000 Japanese patients obtained from Yahoo Japan Corporation. Second, we conducted whole-exome sequencing to detect druggable mutations in the primary tumour. Results: Forty of 59 determinable characters related to the constitution were consistent with the clinical phenotype. Several diseases classified as ‘high risk’ diseases actually occurred during the patient’s clinical course. Of the 129 significant mutations, we identified somatic mutations in BRAF, PIK3CA, and SMAD4 as targets. Conclusion: The dual genomic examination will improve the follow-up observation system to support primary care doctors in the social community for taking care of postoperative cancer patients.",
author = "Naoki Hayashi and Yohsuke Kuroda and Tomoko Saito and Yusuke Tsuruda and Atsushi Niida and hajime otsu and Hidetoshi Eguchi and Takaaki Masuda and Yutaka Suzuki and Shoji Natsugoe and Koshi Mimori",
year = "2019",
month = "9",
day = "10",
doi = "10.1007/s00595-019-01789-7",
language = "English",
volume = "49",
pages = "738--747",
journal = "Surgery Today",
issn = "0941-1291",
publisher = "Springer Japan",
number = "9",

}

TY - JOUR

T1 - A clinical trial of somatic and germline analyses for healthy longevity in a postoperative cancer patient

AU - Hayashi, Naoki

AU - Kuroda, Yohsuke

AU - Saito, Tomoko

AU - Tsuruda, Yusuke

AU - Niida, Atsushi

AU - otsu, hajime

AU - Eguchi, Hidetoshi

AU - Masuda, Takaaki

AU - Suzuki, Yutaka

AU - Natsugoe, Shoji

AU - Mimori, Koshi

PY - 2019/9/10

Y1 - 2019/9/10

N2 - Purpose: Recent developments in molecular-targeted therapies have improved the clinical outcome of cancer patients; however, the issue of adverse effects due to treatments has often gone unconsidered. We herein report the results of a clinical trial of dual genomic analyses for healthy longevity in a postoperative cancer patient. Methods: We performed dual genomic analyses for a representative 79-year-old rectal cancer patient who relapsed with liver metastasis. First, we determined single-nucleotide polymorphisms according to the constitution and disease risk in the genomic DNA from the patient’s saliva by referring to the data of 10,000 Japanese patients obtained from Yahoo Japan Corporation. Second, we conducted whole-exome sequencing to detect druggable mutations in the primary tumour. Results: Forty of 59 determinable characters related to the constitution were consistent with the clinical phenotype. Several diseases classified as ‘high risk’ diseases actually occurred during the patient’s clinical course. Of the 129 significant mutations, we identified somatic mutations in BRAF, PIK3CA, and SMAD4 as targets. Conclusion: The dual genomic examination will improve the follow-up observation system to support primary care doctors in the social community for taking care of postoperative cancer patients.

AB - Purpose: Recent developments in molecular-targeted therapies have improved the clinical outcome of cancer patients; however, the issue of adverse effects due to treatments has often gone unconsidered. We herein report the results of a clinical trial of dual genomic analyses for healthy longevity in a postoperative cancer patient. Methods: We performed dual genomic analyses for a representative 79-year-old rectal cancer patient who relapsed with liver metastasis. First, we determined single-nucleotide polymorphisms according to the constitution and disease risk in the genomic DNA from the patient’s saliva by referring to the data of 10,000 Japanese patients obtained from Yahoo Japan Corporation. Second, we conducted whole-exome sequencing to detect druggable mutations in the primary tumour. Results: Forty of 59 determinable characters related to the constitution were consistent with the clinical phenotype. Several diseases classified as ‘high risk’ diseases actually occurred during the patient’s clinical course. Of the 129 significant mutations, we identified somatic mutations in BRAF, PIK3CA, and SMAD4 as targets. Conclusion: The dual genomic examination will improve the follow-up observation system to support primary care doctors in the social community for taking care of postoperative cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=85062681659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062681659&partnerID=8YFLogxK

U2 - 10.1007/s00595-019-01789-7

DO - 10.1007/s00595-019-01789-7

M3 - Article

AN - SCOPUS:85062681659

VL - 49

SP - 738

EP - 747

JO - Surgery Today

JF - Surgery Today

SN - 0941-1291

IS - 9

ER -